387 related articles for article (PubMed ID: 24216483)
1. Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.
Inoue D; Kitaura J; Togami K; Nishimura K; Enomoto Y; Uchida T; Kagiyama Y; Kawabata KC; Nakahara F; Izawa K; Oki T; Maehara A; Isobe M; Tsuchiya A; Harada Y; Harada H; Ochiya T; Aburatani H; Kimura H; Thol F; Heuser M; Levine RL; Abdel-Wahab O; Kitamura T
J Clin Invest; 2013 Nov; 123(11):4627-40. PubMed ID: 24216483
[TBL] [Abstract][Full Text] [Related]
2. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
[TBL] [Abstract][Full Text] [Related]
3. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
Abdel-Wahab O; Adli M; LaFave LM; Gao J; Hricik T; Shih AH; Pandey S; Patel JP; Chung YR; Koche R; Perna F; Zhao X; Taylor JE; Park CY; Carroll M; Melnick A; Nimer SD; Jaffe JD; Aifantis I; Bernstein BE; Levine RL
Cancer Cell; 2012 Aug; 22(2):180-93. PubMed ID: 22897849
[TBL] [Abstract][Full Text] [Related]
4. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.
Abdel-Wahab O; Gao J; Adli M; Dey A; Trimarchi T; Chung YR; Kuscu C; Hricik T; Ndiaye-Lobry D; Lafave LM; Koche R; Shih AH; Guryanova OA; Kim E; Li S; Pandey S; Shin JY; Telis L; Liu J; Bhatt PK; Monette S; Zhao X; Mason CE; Park CY; Bernstein BE; Aifantis I; Levine RL
J Exp Med; 2013 Nov; 210(12):2641-59. PubMed ID: 24218140
[TBL] [Abstract][Full Text] [Related]
5. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.
Fisher CL; Pineault N; Brookes C; Helgason CD; Ohta H; Bodner C; Hess JL; Humphries RK; Brock HW
Blood; 2010 Jan; 115(1):38-46. PubMed ID: 19861679
[TBL] [Abstract][Full Text] [Related]
6. [Role of ASXL1 mutations in hematological disorders].
Uni M
Rinsho Ketsueki; 2019; 60(6):680-690. PubMed ID: 31281161
[TBL] [Abstract][Full Text] [Related]
7. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
Asada S; Kitamura T
Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
[TBL] [Abstract][Full Text] [Related]
8. Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels.
Inoue D; Matsumoto M; Nagase R; Saika M; Fujino T; Nakayama KI; Kitamura T
Exp Hematol; 2016 Mar; 44(3):172-6.e1. PubMed ID: 26700326
[TBL] [Abstract][Full Text] [Related]
9. A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies.
Inoue D; Fujino T; Sheridan P; Zhang YZ; Nagase R; Horikawa S; Li Z; Matsui H; Kanai A; Saika M; Yamaguchi R; Kozuka-Hata H; Kawabata KC; Yokoyama A; Goyama S; Inaba T; Imoto S; Miyano S; Xu M; Yang FC; Oyama M; Kitamura T
Leukemia; 2018 Jun; 32(6):1327-1337. PubMed ID: 29556021
[TBL] [Abstract][Full Text] [Related]
10. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
[TBL] [Abstract][Full Text] [Related]
11. Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification.
Uni M; Masamoto Y; Sato T; Kamikubo Y; Arai S; Hara E; Kurokawa M
Leukemia; 2019 Jan; 33(1):191-204. PubMed ID: 29967380
[TBL] [Abstract][Full Text] [Related]
12. [Role of ASXL1 mutation in myeloid malignancies].
Sheng MY; Zhou Y; Xu MJ; Yang FC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
[TBL] [Abstract][Full Text] [Related]
13. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Gelsi-Boyer V; Trouplin V; Adélaïde J; Bonansea J; Cervera N; Carbuccia N; Lagarde A; Prebet T; Nezri M; Sainty D; Olschwang S; Xerri L; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
Br J Haematol; 2009 Jun; 145(6):788-800. PubMed ID: 19388938
[TBL] [Abstract][Full Text] [Related]
14. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.
Wang J; Li Z; He Y; Pan F; Chen S; Rhodes S; Nguyen L; Yuan J; Jiang L; Yang X; Weeks O; Liu Z; Zhou J; Ni H; Cai CL; Xu M; Yang FC
Blood; 2014 Jan; 123(4):541-53. PubMed ID: 24255920
[TBL] [Abstract][Full Text] [Related]
15. The role of ASXL1 in hematopoiesis and myeloid malignancies.
Asada S; Fujino T; Goyama S; Kitamura T
Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
[TBL] [Abstract][Full Text] [Related]
16. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
Lin Y; Zheng Y; Wang ZC; Wang SY
Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation by ASXL1 in myeloid malignancies.
Yang FC; Agosto-Peña J
Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
[TBL] [Abstract][Full Text] [Related]
19. HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
Takeda R; Asada S; Park SJ; Yokoyama A; Becker HJ; Kanai A; Visconte V; Hershberger C; Hayashi Y; Yonezawa T; Tamura M; Fukushima T; Tanaka Y; Fukuyama T; Matsumoto A; Yamasaki S; Nakai K; Yamazaki S; Inaba T; Shibata T; Inoue D; Honda H; Goyama S; Maciejewski JP; Kitamura T
Blood; 2020 Oct; 136(14):1670-1684. PubMed ID: 32492700
[TBL] [Abstract][Full Text] [Related]
20. The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model.
Hsu YC; Chiu YC; Lin CC; Kuo YY; Hou HA; Tzeng YS; Kao CJ; Chuang PH; Tseng MH; Hsiao TH; Chou WC; Tien HF
J Hematol Oncol; 2017 Jul; 10(1):139. PubMed ID: 28697759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
